Registration of health products for human use: Niger Republic case (from January 2018 to December 2020)

  • Mahaman Rabiou MAMANE IBRAHIM Faculté des Sciences de la Santé de l’Université de Maradi, Niger.
  • Ousmane ABDOULAYE Faculté des Sciences de la Santé de l'Université de Maradi
  • Rakia ABDOU BAGOUGOU Direction de la Pharmacie et de la Médecine Traditionnelle, Ministère de la Santé Publique de la Population et des Affaires Sociales
  • Fatima GUIET MATI Direction de la Pharmacie et de la Médecine Traditionnelle, Ministère de la Santé Publique de la Population et des Affaires Sociales
  • Mahamadou OUDOU MOSSI MAIGA Laboratoire National de Santé Publique et d’Expertise, Niamey, Niger
  • Hamidou HAROUNA Pharmacie Voie Express, Niamey, Niger
  • Mahaman Laouali HAROUNA AMADOU Faculté des Sciences de la Santé de l’Université de Maradi, Niger.
  • Kassoum JATAOU BAHARI Faculté des Sciences de la Santé de l’Université de Maradi, Niger.
  • Nouhou HAMA AGHALI Faculté des Sciences de la Santé de l’Université de Maradi, Niger.
  • Habsatou MINDAOUDOU Direction de la Pharmacie et de la Médecine Traditionnelle, Ministère de la Santé Publique de la Population et des Affaires Sociales
  • Bachir ILLO Direction de la Pharmacie et de la Médecine Traditionnelle, Ministère de la Santé Publique de la Population et des Affaires Sociales
  • Barira DAN NOUHOU Direction de la Pharmacie et de la Médecine Traditionnelle, Ministère de la Santé Publique de la Population et des Affaires Sociales

Abstract

Objective: Our study aims to make a nomenclature of the pharmaceutical products having received an authorization of sale on the market (MA) in Niger Republic and to describe the profiles of the various applicant laboratories and or manufacturers. We had conducted a retrospective and descriptive study on new applications for registration of health products for human use examined in first intention only by the National Commission for Health Products Approval (NCHPA) from January 2018 to December 2020.


Material and methods: Over this period, 7 sessions of the NCHPA were held, including 3 in 2018, 2 in 2019, and 2 in 2020. In total, 951 dossiers for registration were reviewed in first intention.


Results: It was found that the majority of applicant laboratories (37.22%) as well as manufacturer laboratories (40.38%) were from India. The most represented therapeutic class was antibiotics (21.35%) followed by antimalarial (9.67%). However, the main route of administration was oral (79.28%) with a predominance of tablets (52.47%). Our study had also noted that only 10.10% of the dossiers have been accepted against 86.75% postponed due to lack of required information.


Summary ad conclusion: The national drug nomenclature remains the main document guiding the prescription and dispensing of products with a valid market authorization in the country. This is why all the actors in pharmaceutical logistics must have at hand all the information on the products approved in Niger.

Keywords: Pharmaceutical products, Registration, Regulations, Market Authorization (MA), Niger Republic, WAEMU, National Committee for Health Products Approval (NCHPA)

Downloads

Download data is not yet available.

References

1. Niger Republic. Ordinance No. 97-002 of 10th January 1997 on pharmaceutical legislation. JORN n° 4 of 15; 1997 Feb. p. 153.
2. West African Economic and Monetary Union (UEMOA). Regulation n°04/2020/CM/UEMOA of 28th September 2020, relating to registration procedures for pharmaceutical products for human use in UEMOA member states; 2020 Sept.
3. Assissé-Nowoto MA. Management of the issuance of marketing authorizations (MA) for medicines for human use in Mali in 2019. Thesis of Pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2019 N°12. p.107.
4. Ofirdan A. Approval of medicines for human use in Togo: year 2017. Thesis of Pharmacy. University of Lomé; 2017.
5. Mounkoro K. Evaluation of the registration process of medicines for human use in the Republic of Mali in 2013. Doctoral thesis in pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2015 N°40.
6. Bakabe Mahamadou Roumanatou. “Evaluation of the availability and marketing of medicines after obtaining the marketing authorisation (MA) from the import and wholesale establishments of Bamako”. Thesis of Pharmacy, FMOS/FAPH of USTTB, Bamako; 2008. N°9.p. 82.
7. Kouamba G. A. Drug registration process in Mali: Case of antibiotics and antimalarials in 2016. Thesis of Pharmacy. University of Sciences, Techniques and Technologies of Bamako; 2018 N°40.
8. Coulibaly Ylombou Jeanine. "Evaluation of the respect and application of pharmaceutical regulation in Burkina Faso: the case of special import authorisations for pharmaceutical products". Thesis of Pharmacy, UFR/SDS; Ouagadougou; 2012 N°158.
9. Ministry of Health. Niger Health Statistics Yearbook [Internet]. 2017 [cited 2021 Nov 14]. Available from:
http://www.snis.cermes.net/wp-content/uploads/Annuaire_Statistiques_2017.pdf
10. Severe Malaria Observatory [Internet]. 2018 [cited 2021 Nov 2]. Available from:
https://www.severemalaria.org/fr/pays/niger
Statistics
168 Views | 0 Downloads
How to Cite
MAMANE IBRAHIM, M. R., O. ABDOULAYE, R. ABDOU BAGOUGOU, F. GUIET MATI, M. OUDOU MOSSI MAIGA, H. HAROUNA, M. L. HAROUNA AMADOU, K. JATAOU BAHARI, N. HAMA AGHALI, H. MINDAOUDOU, B. ILLO, and B. DAN NOUHOU. “Registration of Health Products for Human Use: Niger Republic Case (from January 2018 to December 2020)”. International Journal of Drug Regulatory Affairs, Vol. 10, no. 2, June 2022, pp. 62-67, doi:10.22270/ijdra.v10i2.526.